Background: Aspirin use is associated with reduced risk of several cancers. A pooled analysis of 12 case-control studies showed a 10% decrease in ovarian cancer risk with regular aspirin use, which was stronger for daily and low-dose users. To prospectively investigate associations of analgesic use with ovarian cancer, we analyzed data from 13 studies in the Ovarian Cancer Cohort Consortium (OC3). Methods: The current study included 758 829 women who at study enrollment self-reported analgesic use, among whom 3514 developed ovarian cancer. Using Cox regression, we assessed associations between frequent medication use and risk of ovarian cancer. Dose and duration were also evaluated. All statistical tests were two-sided. Results: Women who used aspirin almost daily (!6 days/wk) vs infrequent/nonuse experienced a 10% reduction in ovarian cancer risk (rate ratio [RR] ¼ 0.90, 95% confidence interval [CI] ¼ 0.82 to 1.00, P ¼ .05). Frequent use (!4 days/wk) of aspirin (RR ¼ 0.95, 95% CI ¼ 0.88 to 1.03), nonaspirin nonsteroidal anti-inflammatory drugs (NSAIDs; RR ¼ 1.00, 95% CI ¼ 0.90 to 1.11), or acetaminophen (RR ¼ 1.05, 95% CI ¼ 0.88 to 1.24) was not associated with risk. Daily acetaminophen use (RR ¼ 1.28, 95% CI ¼ 1.00 to 1.65, P ¼ .05) was associated with elevated ovarian cancer risk. Risk estimates for frequent, long-term (10þ years) use of aspirin (RR ¼ 1.15, 95% CI ¼ 0.98 to 1.34) or nonaspirin NSAIDs (RR ¼ 1.19, 95% CI ¼ 0.84 to 1.68) were modestly elevated, although not statistically significantly so. Conclusions: This large, prospective analysis suggests that women who use aspirin daily have a slightly lower risk of developing ovarian cancer ($10% lower than infrequent/nonuse)-similar to the risk reduction observed in case-control analyses. The observed potential elevated risks for 10þ years of frequent aspirin and NSAID use require further study but could be due to confounding by medical indications for use or variation in drug dosing.
through ovulation (2, 3) , inflammation-related exposures such as endometriosis and pelvic inflammatory disease (4, 5) , and circulating biomarkers of inflammation (6, 7) have been associated with ovarian cancer risk.
Inhibition of cyclooxygenase (COX) enzymes in prostaglandin synthesis is a primary mechanism responsible for the anti-inflammatory and antineoplastic effects of nonsteroidal anti-inflammatory drugs (NSAIDs) (8, 9) , and may play a role in ovarian carcinogenesis. Additionally, NSAIDs may suppress ovulation and affect cell proliferation, angiogenesis, and apoptosis of the epithelium (10) . Acetaminophen, another common analgesic and antipyretic, has weak antiinflammatory activity and antigonadotropic effects (11) . It also may inhibit ovarian carcinogenesis through the depletion of glutathione leading to necrosis (12) . Aspirin, nonaspirin NSAIDs, and acetaminophen are widely used, so any increased or decreased cancer risk may have important public health implications.
Cardiovascular disease prevention trials have shown that daily aspirin use is associated with reduced risk and mortality of several malignancies (eg, colorectal cancer) (13) . However, the limited number of women in these trials is insufficient to evaluate ovarian cancer end points (14) .
A recent pooled analysis of 12 case-control studies in the Ovarian Cancer Association Consortium (OCAC) reported a reduced risk of ovarian cancer with aspirin use, particularly for daily aspirin users (15) . High-dose nonaspirin NSAID use, but not acetaminophen, was also associated with lower risk (15) . The few prospective observational studies between aspirin or other NSAID use and ovarian cancer risk have had inconsistent results (16) (17) (18) (19) (20) . Prospective studies avoid potential biases that may occur in case-control studies, including differences between nonresponders and responders among cases or controls or differences in recollection or reporting of medication use after being diagnosed with ovarian cancer. However, the decreased risk observed for aspirin or nonaspirin NSAIDs and the lack of association with acetaminophen in case-control studies argues against substantial differential recall (15) . Further, the exposure window being evaluated in case-control studies is often shortly before cancer diagnosis, during which use may be influenced by preclinical disease. Prospective assessment of analgesic use many years before ovarian cancer diagnosis is necessary to confirm the association with an eye toward improving prevention recommendations. Thus, we evaluated the association between frequent aspirin, nonaspirin NSAID, and acetaminophen use with ovarian cancer risk using prospective individual-level data from the Ovarian Cancer Cohort Consortium (OC3).
Methods

Study Population
The study population included women participating in 16 prospective cohort studies from North America and Europe (Supplementary Table 1 , available online) (16, 17, 19, (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) . Eligible studies were a cohort study or clinical trial with prospective follow-up including women, determination of ovarian cancer end points through questionnaire/medical record follow-up or confirmation by cancer registries, and follow-up for death. This analysis was limited to 13 studies that collected information on frequent aspirin, nonaspirin NSAID, or acetaminophen (paracetamol) use over at least a six-month period (n ¼ 758 829). All studies obtained institutional approval at their respective institutions; participants provided either written informed consent or implicit consent through return of the study questionnaire. The OC3 Data Coordinating Center and analytic approaches were approved by the institutional review board of the Brigham and Women's Hospital.
Exposure Definitions
Medication use was self-reported at enrollment (Supplementary  Table 1 , available online) (16, 17, 19, 21, 22, (24) (25) (26) (27) (29) (30) (31) (32) (33) (34) . Given the rationale for assessment of frequent use based on biologic mechanisms and published research (13) (14) (15) , we focused on frequent medication use (at least 4-5 days/wk) when possible. Frequency was available in 10 of 13 studies (16, 17, 21, 24, 25, (29) (30) (31) (32) , whereas three studies included frequency in their definition of regular medication use (19, 22, 26) . Frequent use was defined as use at least four to five times per week for at least six months' duration; less frequent use or nonregular use/no use were combined to form the reference group. We also evaluated very frequent (daily/almost daily) use for at least 6 months' duration as one of the following: six to seven days per week, seven days per week, or 28 or more days per month (11 studies) (16, 17, 21, 22, 24, 25, (29) (30) (31) (32) . Frequency variables were further divided by duration of use (all medications: !0.5-5, >5-10, >10 years, 9 studies) (16, 19, (24) (25) (26) (30) (31) (32) and aspirin dose (<100 [or "baby aspirin"] and !100 mg, four studies) (16, 19, 23, 31) .
Potential confounding variables were harmonized from the studies as part of a core data set. A priori adjustment factors included baseline age (continuous), body mass index (<20, 20-24.9, 25-29.9, 30-34.9, !35 kg/m 2 ), number of births (0, 1, 2, 3, !4
full-term births), duration of oral contraceptive (OC) use (never, 1, >1-5, >5-10, >10 years), and menopause/duration of menopausal hormone therapy (premenopausal, postmenopausal: never, 5, >5-10, >10 years).
Outcome Definitions
We included epithelial ovarian or peritoneal tumors identified either through cancer registries or medical record review (ICD9 codes 183 and 158; ICD10 codes C56). We first evaluated associations of medications with all tumors combined (ovarian and peritoneal, n ¼ 3514). Second, we evaluated associations for invasive epithelial ovarian cancers (n ¼ 3147), and, third, we evaluated associations for the four most common tumor histotypes: serous (n ¼ 1475, including tumors coded as poorly differentiated), endometrioid (n ¼ 233), mucinous (n ¼ 125), and clear cell (n ¼ 111). The remaining 1203 cases had another histology (eg, mixed) or were missing histology information (n ¼ 817) and were censored at diagnosis date in histologyspecific analyses.
Statistical Methods
Women were excluded from primary analyses if they had a history of cancer (other than nonmelanoma skin cancer) at baseline, bilateral oophorectomy before study entry, or were missing age. We calculated hazard ratios (HRs) and 95% confidence intervals (CIs) using Cox proportional hazards regression to evaluate the association between the analgesic medications and risk of ovarian cancer. Women entered the analysis at age at study entry and contributed person-time until the age at first diagnosis of ovarian cancer (event), death (censored), or end of follow-up (censored), whichever came first. In primary analyses, we pooled data from all cohorts, stratifying on cohort to account for potential differences in baseline hazards. Secondarily, we used meta-analysis of cohort-specific estimates to assess between-study heterogeneity. Associations between analgesic medication use and ovarian cancer histotype were calculated using competing-risks Cox regression (36) . Statistical heterogeneity of associations across histotypes was assessed via likelihood ratio test comparing a model that assumed different associations for the exposure of interest by histotype (full model) with a model with a single estimate across histotypes (reduced model) (37) .
Effect modification by factors that influence inflammation (eg, smoking, body mass index [BMI] , history of chronic disease) and established ovarian cancer risk factors (eg, age, parity, OC use, endometriosis) was evaluated using multiplicative interaction terms, with statistical significance assessed by a likelihood ratio test.
In sensitivity analyses, we considered a common reference group, coding "nonfrequent users" as women who reported no or infrequent use of aspirin, nonaspirin NSAIDs, and acetaminophen to account for analgesic usage patterns. We also excluded women who reported a history of chronic disease at baseline to assess potential indication for medication use and explored the potential for reverse causation by evaluating associations of frequent analgesic use with ovarian cancer cases that occurred less than five years, five to less than 10 years, and 10 or more years after baseline. Another sensitivity analysis considered death a competing risk (rather than censoring). Exposure curves from survivor function plots were parallel, suggesting no deviation from proportional hazards. All statistical tests were two-sided, and P values of less than .05 were considered statistically significant; analyses were performed using SAS 9.1.
Results
Study Characteristics
The proportion of women reporting frequent analgesic use increased with age; for example, among women reporting frequent aspirin use, 17.7% were younger than age 50 years, whereas 52.2% were 60 years of age or older (Table 1) . Compared with women who did not use aspirin or who used it infrequently, women who frequently used aspirin were more likely to be older, be postmenopausal, have a history of a chronic disease, have higher BMI, and were less likely to have previously used OCs. Average follow-up after exposure assessment was 10.8 years (maximum ¼ 18.9 years); individual cohort follow-up is reported in Supplementary Table 1 (available online).
Aspirin
Women who used aspirin at least four to five times per week (n ¼ 851 exposed cases [events]) developed ovarian cancer at about the same rate as women who did not use aspirin or used it only infrequently (HR ¼ 0.95, 95% CI ¼ 0.88 to 1.03) ( Table 2) . However, compared with infrequent/nonusers, women reporting daily or almost daily use (at least 6 days/wk or more, n ¼ 449 cases) had a 10% reduction in ovarian cancer risk (HR ¼ 0.90, 95% CI ¼ 0.82 to 1.00, P ¼ .05). This association was statistically significant for women reporting daily or almost daily use for 0.5 to less than five years' duration (HR ¼ 0.79, 95% CI ¼ 0.63 to 0.99, P ¼ .04, n ¼ 87 cases) and was suggestively associated for daily users of five to 10 years' duration (HR ¼ 0.88, 95% CI ¼ 0.65 to 1.18, n ¼ 50 cases). Conversely, women who frequently used (vs infrequent/nonuse) aspirin for long durations (!10 years at baseline) had a non-statistically significantly elevated risk of ovarian cancer (HR ¼ 1.15, 95% CI ¼ 0.98 to 1.34, P ¼.09, n ¼ 212 cases). No associations were observed when analyzing aspirin dose or other patterns of duration. In analyses by histotype (Table 3) , results for serous ovarian cancers were similar to those seen for all ovarian cancer: compared with infrequent/ nonuse, daily aspirin use was associated with a 15% decrease for serous tumors (95% CI ¼ 0.71 to 1.00, n ¼ 159 cases), whereas 10 or more years of frequent aspirin use was related to a suggestively elevated risk (HR ¼ 1.27, 95% CI ¼ 0.99 to 1.62, n ¼ 74 cases). A similar pattern was observed for clear cell tumors; however, risk estimates were imprecise due to limited numbers. No associations were observed for endometrioid or mucinous tumors.
Nonaspirin NSAIDs
Women who frequently used nonaspirin NSAIDs had a similar rate of ovarian cancer as infrequent/nonusers (HR ¼ 1.00, 95% CI ¼ 0.90 to 1.11, n ¼ 426 cases) ( Table 2) . Longer duration or daily frequency of nonaspirin NSAIDs was not related to ovarian cancer risk, although the risk estimate for ovarian cancer for frequent, frequent, long-duration (>10 years) of use of nonaspirin NSAIDs was suggestively elevated (HR ¼ 1.19, 95% CI ¼ 0.84 to 1.68, n ¼ 36 cases). In analyses by histotype, women who frequently used (vs infrequent/nonuse) nonaspirin NSAIDs for long durations had an increased risk of serous tumors than women who used them infrequently or not at all (HR ¼ 2.06, 95% CI ¼ 1.14 to 3.74, n ¼ 10 cases) ( Table 3) .
Acetaminophen
Frequent use compared with infrequent/nonuse of acetaminophen was not associated with ovarian cancer risk (HR ¼ 1.05, 95% CI ¼ 0.88 to 1.24, n ¼ 152 exposed cases) ( Table 2 ). However, there was a suggestive elevated risk with daily acetaminophen use (HR ¼ 1.28, 95% CI ¼ 1.00 to 1.65, P ¼ .05, n ¼ 71 cases) that was stronger for serous tumors (HR ¼ 1.70, 95% CI ¼ 1.14 to 2.55, n ¼ 26 cases) ( Table 3) .
Additional Analyses
There was little heterogeneity across studies (data not shown). Risk estimates were generally similar across age strata (Supplementary Table 2 , available online). Compared with infrequent/nonusers, daily aspirin use was related to reduced ovarian cancer risk among women younger than age 50 years (HR ¼ 0.89, 95% CI ¼ 0.43 to 1.84), age 50 to 59 years (HR ¼ 0.92, 95% CI ¼ 0.73 to 1.17), and age 60 to 69 years (HR ¼ 0.88, 95% CI ¼ 0.75 to 1.04) at baseline but was null for women age 70 years or older (HR ¼ 1.05, 95% CI ¼ 0.82 to 1.36, P interaction ¼ .73). Daily acetaminophen use was only associated with increased ovarian cancer risk among women age 70 years or older (HR ¼ 1.78, 95% CI ¼ 1.17 to 2.72, P interaction < .001). Results were similar across strata of other ovarian cancer risk factors (data not shown).
Results were similar in analyses restricted to invasive ovarian cancers, utilizing a common reference group, and accounting for death as a competing risk (data not shown). In analyses excluding women with a history of chronic disease, elevated risk estimates with frequent long-duration use of aspirin or 
Discussion
We observed a 10% reduced ovarian cancer risk for daily aspirin use, although only for women who had used aspirin for less than 10 years; use for 10 or more years was associated with a null or slightly elevated risk. Nonaspirin NSAID and acetaminophen use was not clearly related to ovarian cancer risk overall; however, we observed an increased risk for very frequent (daily/ almost daily for at least six months) acetaminophen use. Further, like aspirin, long-duration, frequent nonaspirin NSAID use was associated, at least suggestively, with elevated risk of ovarian cancer. The modestly reduced risk for daily aspirin use is consistent with previous observations from case-control studies (15) , although the suggestively elevated risk with long duration of frequent analgesic use requires further evaluation. Importantly, in this analysis, we were able to evaluate patterns of duration to characterize a dose-response association; however, unlike colorectal cancer, in which longer duration of use is associated with further risk reductions (38) , the reduced risk of ovarian cancer with frequent aspirin use was only apparent with short to moderate duration (the largest exposure stratum) and appeared null or slightly elevated with longer-duration use (!10 years). This may be because those who frequently used aspirin for many years may be more likely to use standard vs low-dose aspirin. That said, availability of data on very long durations of use was limited, as evidenced by the less precise estimates in this group. A better understanding of the relationship between frequency and duration of use leveraging updated exposure data is needed to assess the potential causality of the daily aspirin-ovarian cancer relationship, including ascertainment of use during potentially critical time periods given that the increased risk for long-duration use was strongest for cases diagnosed early in follow-up. Further, consideration of associations for daily aspirin use and its timing/duration with ovarian cancer is needed to fully assess potential for primary prevention, particularly given the relatively low prevalence of ovarian cancer and risk-related adverse events (eg, upper gastrointestinal bleeding). Consistent with our results, pooled analyses of clinical trial data demonstrate that daily aspirin use is most relevant for risk reduction of colorectal cancer and cancer risk overall (39), as alternate dosing trials (higher dose or every other day use) did not show clear benefits (40) .
The previous pooled case-control study and our current study support that daily aspirin use is associated with lower ovarian cancer risk. The weaker association in the prospective studies vs case-control studies is similar to results for breast cancer risk (14) . Although recall bias may lead to a stronger association in case-control studies, we would expect this to attenuate any true reductions in risk with daily aspirin use. Alternately, considering analgesic use collected at study entry may lead to misclassification of exposure status over follow-up (which averaged more than a decade long) that could attenuate results. Conversely, we observed a consistently elevated ovarian cancer risk with frequent, long-duration use of aspirin and nonaspirin NSAIDs, suggesting potential confounding by medical indications for long-term use. We could not directly address this as indication for use was not collected in most studies. To address this in sensitivity analyses, we excluded women who *Hazard ratios and 95% confidence intervals were estimated from Cox proportional hazards models stratified by study cohort and adjusted for baseline age (continuous), body mass index (<20, 20-24.9, 25-29.9, 30-34.9, !35 kg/m 2 ), number of births (none, one, two, three, four or more full-term births), duration of oral contraceptive (OC) use (never, 1, >1-5, >5-10, >10 years), and duration of menopausal hormone therapy use (premenopausal, never, 5, >5-10, >10 years). CI ¼ confidence interval; HR ¼ hazard ratio; NSAID ¼ nonsteroidal anti-inflammatory drug. †P value was calculated using a two-sided Wald test. ‡Frequent: use at least $4-5 days/wk for 6 months or longer. §Daily: use at least $6-7 days/wk or !28 days per month for 6 months or longer. (15) , based on more than 400 exposed cases (odds ratio for daily vs nonregular use ¼ 0.95, 95% CI ¼ 0.74 to 1.23). Acetaminophen and nonaspirin NSAIDs are commonly used interchangeably; however, acetaminophen has weak antiinflammatory properties and may have gonadotrophic effects (11) , supporting the different associations we observed between NSAIDs and acetaminophen in our study and suggesting different anti-inflammatory effects or other mechanisms of action (8, 9, 11) . Importantly, the increased risk with daily acetaminophen use observed in this study was based on a limited number of exposed cases and should be interpreted with caution.
ARTICLE
The consistent positive relationship for frequent long-duration use of aspirin or nonaspirin NSAIDs with serous disease may suggest that long-term users likely have other factors that increase inflammation and thus risk of this histotype. Some data suggest that serous tumors may be more strongly related to inflammatory factors. For example, aggressive high-grade serous tumors have been more commonly associated with inducible nitric oxide synthase and other inflammatory markers than low-grade tumors (41) . Further, prediagnostic circulating inflammatory marker, C-reactive protein, has been associated with the serous histotype (6, 42) . Lifetime ovulations also were more strongly associated with tumors expressing p53 (43), a hallmark of serous disease (44) .
The prospective design of the pooled studies precludes recall bias. Additional strengths of the study include the large sample size, the ability to identify deaths as well as capture loss to follow-up, and the ability to account for many known and suspected risk factors for ovarian cancer. Limitations included the use of self-reported exposure data, limited information on lowdose aspirin use, and limited data on health conditions or medical indications underlying long-term analgesic use. The combination of long-term follow-up and ascertainment of exposure at baseline (in most studies) mean that individuals could have started or stopped use during follow-up, which would contribute to measurement error. Further, information on duration of use at baseline may not adequately represent exposure duration, as such confounding by indication may not fully explain the elevated risks. Residual confounding by age-related factors may also be present; however, we did not observe substantial differences in associations across age strata.
The incidence of ovarian cancer is low; thus, our modest findings are unlikely to alter the balance of more common and clinically significant risks and benefits associated with daily aspirin use. However, the associations stratified by age at baseline provide information relevant to current US Preventive Services Task Force recommendations regarding aspirin use for cardiovascular prevention (45) , as decreased ovarian cancer risk estimates associated with daily aspirin use were only observed among women younger than age 70 years. The USPSTF does not recommend frequent aspirin use in women age 70 years or older because of increased risk for adverse events. Although the potential increased risk associated with daily acetaminophen and frequent aspirin and nonaspirin NSAID use for more than 10 years' duration requires further study, daily aspirin use may provide a very modestly reduced risk with respect to incident ovarian cancer. The funding agency did not have any role in the design of the study; the collection, analysis, or interpretation of the data; the writing of the manuscript; or the decision to submit the manuscript for publication.
Preliminary results from this study were presented at the AACR Rivkin Ovarian Cancer Meeting (September 2016) and at the NCI Cohort Consortium Annual Meeting (November 2016, same abstract).
